2.1 PBS, Authority Prescriptions & Special Access Scheme

2.1 PBS, Authority Prescriptions & Special Access Scheme

Quick Answer: Under the Pharmaceutical Benefits Scheme (PBS), pharmacists supply subsidised medicines only when the prescription and patient meet PBS rules. Authority items need approval or a valid STREAMLINED code; brand substitution follows a-flagging and prescriber directions; Safety Net reduces contributions after a yearly threshold; and unapproved medicines may be supplied only through lawful pathways such as the Special Access Scheme (SAS).

Standard 1.3 of the National Competency Standards expects interns to practise within Australia's legal framework. PBS and SAS decisions are high-yield because small paperwork or eligibility errors change whether supply is lawful, claimable, or clinically appropriate.

PBS Versus Private (Non-PBS) Supply

The PBS is the Australian Government scheme that subsidises many listed medicines for eligible people (for example Medicare-eligible patients holding a valid Medicare card or equivalent eligibility arrangements). A PBS prescription must meet the scheme's legal and administrative requirements for the claim to be valid. A private prescription is not claimed as a PBS benefit: the patient pays the full private price (or uses other funding), but the medicine's schedule still governs whether supply is lawful.

Exam trap: An S4 medicine on a private script is still prescription-only. "Private" means funding pathway, not "OTC".

What Pharmacists Must Check on PBS Scripts

Before supply and claim, work through a disciplined checklist:

1. Patient eligibility — Medicare (or other eligible) details match the person presenting, and any concessional evidence is current if a concessional contribution is claimed.
2. Prescriber authority — Prescriber is authorised to prescribe that PBS item (including any specialist or authority constraints on the listing).
3. Item identity — Drug, form, strength, quantity, and repeats align with the PBS listing and any maximum quantities.
4. Indication / authority — If the item is Authority Required, approval or STREAMLINED code is present and appropriate.
5. Prescription formalities — Date, patient identifiers, prescriber details, signature (or compliant electronic prescription), and any required particulars for the schedule (especially S8).
6. Clinical and legal fitness to supply — No red flags that make supply unsafe or unlawful even if paperwork looks complete.

If a patient presents with a script that cannot be claimed as PBS (wrong quantity, missing authority, non-listed indication for that brand), options may include contacting the prescriber for correction, supplying privately if lawful, or declining supply when the prescription is inadequate.

Authority Required Versus Authority Required (STREAMLINED)

Many PBS items are restricted so that subsidy applies only when clinical criteria are met.

Authority Required (non-streamlined)

The prescriber must obtain prior authority approval (classically via Services Australia authority arrangements) before writing or finalising the prescription for PBS supply. The pharmacist should see evidence of authority on the prescription (for example an authority approval number) as required for that item. Without valid authority, do not process a PBS authority claim as if it were approved.

Authority Required (STREAMLINED)

For STREAMLINED items, the prescriber attests that the patient meets published streamlined criteria and writes a streamlined authority code on the prescription (or equivalent electronic field). The pharmacist does not ring for a new approval number in the same way as non-streamlined authority, but must still check:

• A streamlined code is present and appears consistent with the item/listing
• Quantity and repeats match what the listing allows under that authority pathway
• Patient and clinical context are not obviously inconsistent with legitimate use (professional judgment remains)

Intern scenario — STREAMLINED authority: A patient presents an e-prescription for a STREAMLINED PBS medicine. The code field is blank. The correct action is not to invent a code or "guess" a common one. Contact the prescriber for a compliant script, or consider lawful private supply only if the medicine and prescription otherwise allow it and the patient accepts private pricing—and document the decision path.

Brand Substitution and A-Flagging (High Level)

PBS brand substitution (generic substitution) is tightly controlled:

• Medicines may be treated as interchangeable for substitution purposes when they are a-flagged as equivalent under PBS arrangements.
• If the prescriber has indicated brand substitution not permitted (or equivalent direction), supply the brand prescribed (or resolve with the prescriber).
• Substitution decisions still require patient consent and professional judgment (allergy to excipients, previous intolerance, therapeutic index concerns).

Do not confuse a-flagging with "any brand of the same drug is always fine." Bioequivalence flagging, formulation differences, and device familiarity (for example inhalers) all matter in practice.

Safety Net (Brief)

The PBS Safety Net tracks eligible PBS (and certain RPBS) patient contributions over a calendar year. Once a family's recorded expenditure reaches the Safety Net threshold, further PBS medicines for that family are supplied at a reduced contribution for the rest of that year (concessional and general thresholds differ). Pharmacists support accurate recording (including Safety Net cards/records where used) so patients receive the entitlement they have earned. Exact dollar thresholds change over time—know the concept, not memorised figures, for the intern exam.

Special Access Scheme (SAS)

The Special Access Scheme provides pathways for access to unapproved therapeutic goods (medicines not on the Australian Register of Therapeutic Goods for the intended use, or not registered at all) when clinically justified. High-level categories:

When SAS paperwork matters for supply: Treat SAS as a legal supply pathway, not a clinical preference label. Before releasing an unapproved medicine, confirm:

1. The correct SAS category pathway is being used for that product and patient situation
2. Prescriber obligations (application, notification, informed consent discussions) align with category rules
3. The product identity, quantity, and patient match the authorisation/notification
4. Storage, labelling, counselling, and records meet professional standards for an unapproved product

Intern scenario — SAS request: A patient asks the pharmacy to "order that overseas unapproved tablet" without any SAS documentation or clear prescriber pathway. Supply is not a simple wholesale order. Direct them to their specialist/prescriber to establish the lawful SAS (or other) pathway; do not improvise import or supply.

Intern scenario — non-PBS S4 supply: A patient has a valid private prescription for an S4 medicine that is not being claimed on PBS (patient choice, non-listed brand/quantity, or overseas visitor without PBS eligibility). You may supply as private if prescription and schedule requirements are met, price privately, and counsel as usual. Missing PBS authority is irrelevant to private supply—but missing S4 prescription formalities is not.

Professional Decision Pattern for Exam Items

When a stem involves PBS, authority, or SAS, ask in order:

1. Is supply schedule-lawful? (S2–S8 rules)
2. Is the prescription formally valid?
3. Is PBS claiming allowed? (listing, authority, eligibility, quantity)
4. If not PBS, is private supply appropriate and accepted?
5. If unapproved, is there a SAS/other lawful pathway with paperwork?

That sequence prevents the common error of focusing only on subsidy while missing legality—or the reverse.

Exam Focus Summary

• Distinguish PBS entitlement from private supply and from schedule legality
• Treat STREAMLINED codes as required particulars, not optional annotations
• Use a-flagging + prescriber brand directions for substitution
• Explain Safety Net as a yearly contribution threshold mechanism
• Map SAS A/B/C to purpose and documentation discipline for unapproved medicines